Physician profile
Marcus Medrano
NPI 1629697230
$5,064.88
in general payments reported to CMS, 2019-2025
20 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,674 · 2022: $1,918 · 2023: $1,223 · 2024: $125 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,234.65 | 2021-2024 | Airsupra, Farxiga, Tezspire |
| Novo Nordisk INC | $1,041.35 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $706.94 | 2021-2023 | |
| Amgen INC. | $498.20 | 2021-2023 | Otezla, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $234.08 | 2022-2023 | |
| Glaxosmithkline, LLC. | $206.05 | 2022-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $206.01 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.13 | 2021-2022 | |
| Lilly USA, LLC | $120.21 | 2021-2023 | Trulicity, Mounjaro |
| Corcept Therapeutics | $114.40 | 2022 | |
| Mylan Specialty L.P. | $101.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $96.80 | 2021-2023 | |
| Amarin Pharma, INC. | $80.81 | 2021-2022 | |
| Genentech USA, INC. | $73.75 | 2021 | |
| Pfizer INC. | $68.02 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $35.35 | 2021 | |
| Abbott Laboratories | $21.06 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $21.06 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $11.96 | 2022 | |
| Esperion Therapeutics, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Medrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.